Highest-materiality recent filing
Boundless Bio Q1 2026 net loss $13.6M; cash $92.8M provides runway into H2 2028
Cash, cash equivalents, and short-term investments $92.8M as of March 31, 2026.
Boundless Bio terminates 80,168 sq ft San Diego lease; pays $10M, forfeits $0.5M deposit
Lease originally set to expire Oct 2034; terminated effective May 31, 2026.
Net loss of $12.9M for Q4 2025 and $58.2M for FY2025, vs $16.4M and $65.4M in same periods of 2024.
Boundless Bio Q3 net loss narrows to $13.9M; cash $117.6M supports ops into 2028
Net loss of $13.9M vs $16.5M in Q3 2024; R&D expenses $10.7M (down 24% YoY).
Boundless Bio Q2 net loss $15.7M; cash $127.1M funds operations into H1 2028
Net loss $15.7M in Q2 2025 versus $17.0M in Q2 2024; R&D expenses fell to $12.2M from $14.7M.
Boundless Bio annual meeting elects two directors, ratifies KPMG as auditor
Christine Brennan, Ph.D. elected as Class I director with 9,252,440 votes for and 5,046,258 withheld; 3,540,518 broker non-votes.
Boundless Bio restructures pipeline, cuts workforce 33%, discontinues BBI-355 monotherapy
Workforce reduction of ~1/3; expects $1.2M one-time costs, substantially completed in Q2 2025.
Boundless Bio reports Q1 2025 net loss $15.8M; $138.3M cash; BBI-355 data due H2 2025
Cash, cash equivalents, and short-term investments totaled $138.3M as of March 31, 2025, providing runway into 2027.
Boundless Bio enters $14.5M ATM equity distribution agreement with Jefferies
Company may sell up to $14.5M of common stock via at-the-market offerings through Jefferies LLC.
Boundless Bio Q4 & FY 2024 net loss $65.4M; cash $152.1M; BBI-355 data expected H2 2025
Net loss $16.4M in Q4 2024, full year $65.4M (vs $49.4M in 2023); R&D spend rose to $55.3M.
Boundless Bio stops BBI-825 trial, CMO and CBO depart; cash runway extends to 2027
BBI-825 Phase 1/2 STARMAP trial discontinued due to lack of dose-proportional PK, increased development costs, and competitive landscape changes.
Boundless Bio Q3 net loss $16.5M; cash $167.1M, runway into Q4 2026
Net loss of $16.5M for Q3 2024 vs $13.2M in Q3 2023; R&D expenses $14.1M.
Boundless Bio CFO Jami Rubin steps down; David Hinkle named principal financial officer
Jami Rubin resigned as CFO and Treasurer effective October 11, 2024.
Boundless Bio reprices options for execs to $3.56; CEO Hornby holds 1.15M repriced options
Exercise price reduced to $3.56 (Aug 19, 2024 close) for options originally priced at or above $3.71.
Boundless Bio Q2 net loss $17M; delays BBI-355 combo data to H2 2025
Net loss of $17.0M for Q2 2024 vs $12.4M in Q2 2023; R&D expense $14.7M, G&A $4.7M.
Boundless Bio Q1 net loss $15.4M; cash $105M; IPO adds $100M; BBI-825 trial dosed
Net loss $15.4M in Q1 2024 vs $11.7M in Q1 2023; R&D expenses $13.1M vs $9.5M.
Boundless Bio completes IPO of 6.25M shares at $16.00, raising $100M gross
IPO closed April 2, 2024; 6,250,000 shares sold at $16.00 per share.
On October 14, 2024, Boundless Bio, Inc. (the “Company”) announced that Jami Rubin, the Company’s Chief Financial Officer and Treasurer, stepped down from her role with the Company.
As of the Effective Date, David Hinkle, the Company’s Senior Vice President, Finance & Controller, was appointed to also serve as the Company’s Treasurer, principal financial officer, and principal accounting officer.
Max materiality 0.85 · Median 0.60 · Most common event earnings